L. Wright

发表

Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities

D. Behm, R. Bentley, C. Doe, 2007, Journal of Pharmacology and Experimental Therapeutics.

Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.

R. Hamatake, Suoming Zhang, S. Baker, 2012, Journal of medicinal chemistry.

Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.

R. Hamatake, Z. Hong, Shawn P. Williams, 2014, Journal of medicinal chemistry.

Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.

Z. Ni, Suoming Zhang, S. Baker, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.

Z. Ni, P. Rowland, S. Baker, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.

Z. Ni, Suoming Zhang, S. Baker, 2010, Bioorganic & medicinal chemistry letters.

Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.

E. Furfine, W. Kazmierski, A. Spaltenstein, 2004, Bioorganic & medicinal chemistry letters.

Expression, purification, and characterization of an enzymatically active truncated human rho-kinase I (ROCK I) domain expressed in Sf-9 insect cells.

S. Khandekar, E. Hu, R. Kirkpatrick, 2006, Protein and peptide letters.

Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.

R. Hamatake, Suoming Zhang, S. Baker, 2012, Bioorganic & medicinal chemistry letters.

Acyclic cyanamide-based inhibitors of cathepsin K.

L. Shewchuk, A. Hassell, Aaron B. Miller, 2005, Bioorganic & medicinal chemistry letters.

A structural screening approach to ketoamide-based inhibitors of cathepsin K.

K. Wells-Knecht, Aaron B. Miller, D. N. Deaton, 2005, Bioorganic & medicinal chemistry letters.

Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles.

F. Tavares, Aaron B. Miller, D. N. Deaton, 2005, Bioorganic & medicinal chemistry letters.

Initial binding of 2'-deoxynucleoside 5'-triphosphates to human immunodeficiency virus type 1 reverse transcriptase.

S. Hopkins, G. Painter, P. Furman, 1991, The Journal of biological chemistry.

Design of small molecule ketoamide-based inhibitors of cathepsin K.

K. Wells-Knecht, D. N. Deaton, L. Wright, 2004, Bioorganic & medicinal chemistry letters.

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.

S. Semus, D. Behm, R. Bentley, 2008, Journal of medicinal chemistry.

Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.

J. A. Ray, L. Shewchuk, A. Hassell, 2006, Bioorganic & medicinal chemistry letters.

Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.

E. Furfine, W. Kazmierski, A. Spaltenstein, 2004, Bioorganic & medicinal chemistry letters.

Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.

F. Salituro, E. Furfine, W. Kazmierski, 2000, Bioorganic & medicinal chemistry letters.

Exploration of the P1 SAR of aldehyde cathepsin K inhibitors.

L. Shewchuk, E. Furfine, A. Hassell, 2004, Bioorganic & medicinal chemistry letters.

Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.

S. Semus, D. Behm, R. Bentley, 2007, Journal of medicinal chemistry.

Optimization of pyrrolidinone based HIV protease inhibitors.

E. Furfine, Ronda G. Davis-Ward, C. W. Andrews, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.

Z. Ni, Suoming Zhang, S. Baker, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.

E. Furfine, R. Hazen, David J. Reynolds, 2005, Bioorganic & medicinal chemistry letters.

A Thermodynamic Analysis of the Binding of Nucleic Acid to HIV-1 Reverse Transcriptase

S. Hopkins, G. Painter, C. W. Andrews, 1991 .

Measurement of hemoglobin synthesis rate in vivo using a stable isotope method.

K. A. Wolfe, J. Hibbert, A. Abd-Elfattah, 2001, Analytical biochemistry.

Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.

S. Semus, M. Head, D. Behm, 2007, Journal of medicinal chemistry.

New, potent P1/P2-morpholinone-based HIV-protease inhibitors.

E. Furfine, W. Kazmierski, A. Spaltenstein, 2006, Bioorganic & medicinal chemistry letters.

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

L. Shewchuk, A. Hassell, R. Gampe, 2006, Bioorganic & medicinal chemistry letters.

Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.

F. Tavares, Aaron B. Miller, D. N. Deaton, 2004, Journal of medicinal chemistry.

Human Immunodeficiency Virus

E D Blair, R. Myers, G. Palù, 1996, The Journal of Biological Chemistry.

Novel and potent cyclic cyanamide-based cathepsin K inhibitors.

L. Shewchuk, A. Hassell, F. Tavares, 2005, Bioorganic & medicinal chemistry letters.

Novel and Potent Cyclic Cyanamide‐Based Cathepsin K Inhibitors.

L. Shewchuk, A. Hassell, F. Tavares, 2005 .

Recombinant human immunodeficiency virus type 1 reverse transcriptase is heterogeneous.

G. Painter, J. Wilson, J. L. Martin, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Role of desolvation energy in the nonfacilitated membrane permeability of dideoxyribose analogs of thymidine.

G. Painter, L. Wright, 1992, Molecular pharmacology.

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.

K. Wells-Knecht, F. Tavares, D. N. Deaton, 2004, Bioorganic & medicinal chemistry letters.

Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery.

J. Briand, N. Campobasso, J. Axten, 2010, ACS medicinal chemistry letters.

P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY

R. Hamatake, Z. Hong, R. Crosby, 2014 .

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.

J. A. Ray, L. Shewchuk, A. Hassell, 2005, Bioorganic & medicinal chemistry letters.

Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.

D. N. Deaton, L. Wright, L. Miller, 2004, Journal of Medicinal Chemistry.

Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease.

E. Furfine, W. Kazmierski, A. Spaltenstein, 2002, Bioorganic & medicinal chemistry letters.

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

L. Shewchuk, A. Hassell, K. Wells-Knecht, 2004, Journal of medicinal chemistry.

Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.

William McDowell, Yang Liu, Dazhong Fan, 2010, Bioorganic & medicinal chemistry letters.